Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lingjun Ma
Observed names:
L. Ma,
Lin-xiaoxi Ma,
Lumei Ma
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Jiangsu Province Hospital,
Nanjing Medical University
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Gansu University of Traditional Chinese Medicine,
Fudan University Shanghai Cancer Center,
Jiangsu Province Hospital,
Chinese People's Liberation Army,
Nanjing Medical University
show all 7
ORCID:
0009-0009-2140-4569
Observed ORCID:
0009-0009-2140-4569
OpenAlex ID:
A5016787445
[Research progress on biomarkers of sepsis-associated acute kidney injury].
2024
·
Jiangming Zhang
, Minjun Qi
, et al.
·
PubMed
·
5
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer
2025
·
Li Chen
, Shu-hao Jiang
, et al.
·
Molecular Therapy
·
4
[Construction and validation of a risk nomogram for sepsis-associated acute kidney injury in intensive care unit].
2024
·
Jiangming Zhang
, Minjun Qi
, et al.
·
PubMed
·
3
Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer
2025
·
Lingjun Ma
, Ran Zheng
, et al.
·
Cancer Research and Treatment
·
1
Omission of axillary lymph node dissection in patients with breast cancer with axillary pathological complete response confirmed by stained region lymph node biopsy after neoadjuvant systemic therapy (SrLNB study): study protocol for a single-arm, single-centre, phase-II trial
2025
·
Lingjun Ma
, Rui Chen
, et al.
·
BMJ Open
·
1
PDF
74P The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients (pts) with locally recurrent or metastatic triple-negative breast cancer (TNBC): A multi-cohort, phase II trial
2022
·
L. Liu
, L. Fan
, et al.
·
Immuno-Oncology Technology
·
1
PDF
Abstract P3-11-14: Differential response to neoadjuvant antiHER2 therapy between HER2 2+ISH+ and HER2 3+ in HER2-positive breast cancer: Is HER2 2+ISH+ a distinct subtype?
2025
·
Lingjun Ma
, Lexin Wang
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
7
Citation count:
15
H-index:
3
I10-index:
Year
Topic
Type